DNAtrix Receives European Medicines Agency PRIME Designation
DNAtrix, a clinical stage biotechnology company developing virus-driven immunotherapies for cancer, announced that the European Medicines Agency (EMA) has granted PRIority MEdicines…
Read More...
Read More...